Search

Displaying results 2571 - 2580 of 10000 in total
  1. Drug

    Fruquintinib

    go.drugbank.com/drugs/DB11679
    ApprovedInvestigational

    Tumor angiogenesis is one of the most critical biological processes for increasing oxygen and nutrient supply to cancer cells, and the VEGF/VEGFR pathway is one of the most critical pathways for this phenomenon … The first approach can be exemplified by [bevacizumab], a VEGF-A trap antibody.

    Categories: Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors
  2. Drug

    Lefamulin

    go.drugbank.com/drugs/DB12825
    Approved

    Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. … A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus.

  3. Drug

    Levamlodipine

    go.drugbank.com/drugs/DB09237
    ApprovedInvestigational

    [L1484] The names S-amlodipine and levamlodipine may be used interchangeably as both substances are the same, however. … [L10833] Levamlodipine belongs to the dihydropyridine group of calcium channel blockers.[L10833] This medication was first marketed in Russia and India before being granted FDA approval.

  4. Drug

    L-Glutamine

    go.drugbank.com/drugs/DB00130
    ApprovedInvestigationalNutraceutical

    It is the principal carrier of nitrogen in the body and is an important energy source for many cells. … An oral formulation of L-glutamine was approved by the FDA in July 2017 for use in sickle cell disease [L892]. This oral formulation is marketed under the tradename Endari by Emmaus Medical.

  5. Drug

    Esketamine

    go.drugbank.com/drugs/DB11823
    ApprovedInvestigational

    Esketamine is the s-enantiomer of [Ketamine]. Ketamine is a mixture of two enantiomers (mirror image molecules). This is the first time that the FDA has approved esketamine for any use. … The FDA approved ketamine (Ketalar) in 1970.

    Categories: NMDA Receptor Antagonists, Non-Competitive N-Methyl D-Aspartate (NMDA) Receptor Antagonists
  6. Drug

    Calaspargase pegol

    go.drugbank.com/drugs/DB14730
    ApprovedInvestigational

    SC) linker to create a stable molecule which increases the half-life and decreases the dosing frequency [FDA label], [A40270]. … Asparaginase is an important agent used to treat acute lymphoblastic leukemia (ALL) [A40270].

  7. Drug

    Roxadustat

    go.drugbank.com/drugs/DB04847
    ApprovedInvestigational

    It works by reducing the breakdown of the hypoxia-inducible factor (HIF), which is a transcription factor that stimulates red blood cell production in response to low oxygen levels. … [A245393] Roxadustat was first approved by the European Commission in August 2021.[L40323]

  8. Drug

    Carbetocin

    go.drugbank.com/drugs/DB01282
    ApprovedInvestigational

    It is an analogue of oxytocin, and its action is similar to that of oxytocin -- it causes contraction of the uterus. … Carbetocin is a drug used to control postpartum hemorrhage, bleeding after giving birth.

  9. Drug

    Pegcetacoplan

    go.drugbank.com/drugs/DB16694
    ApprovedInvestigational

    [L34095] In February 2023, pegcetacoplan for intravitreal use was approved by the FDA for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration.[L45354] … [A235000,L34095] Prior to its FDA approval, patients with PNH were typically treated with the C5 inhibiting monoclonal antibody [eculizumab].

  10. Drug

    Nuvaxovid

    go.drugbank.com/drugs/DB15810
    ApprovedInvestigational

    [L49111] In the fall of 2024, an updated formulation covering the Omicron JN.1 subvariant was approved for use in Canada and the US.[L51394,L51399] … SARS-CoV-2, the causative agent of COVID-19, relies on the interaction between its trimeric spike (S) glycoprotein and angiotensin-converting enzyme 2 (hACE2) expressed on host cells in order to establish